Slide 1: Second Quarter 2019 Financial Results & Business Update
Second Quarter 2019 Financial Results & Business Update July 25, 2019 Exhibit 99.2
Slide 2: Forward-Looking Statements and Non-GAAP Financial Information
Forward-Looking Statements and Non-GAAP Financial Information Certain statements set forth in this presentation constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: the co
Slide 3: Second Quarter Earnings Call Agenda
Q2 2019 Financial Results Jim Frates, Chief Financial Officer Pipeline and R&D Update Craig Hopkinson, Chief Medical Officer Business Update Richard Pops, Chief Executive Officer Second Quarter Earnings Call Agenda
Slide 4: Second Quarter 2019 Revenue Summary
Second Quarter 2019 Revenue Summary In millions, except % Q2’19 Q2’18 ∆ Q2’19 vs. Q2’18 VIVITROL® $88.2 $76.2 16% ARISTADA® $48.4 $33.6 44% Manufacturing & Royalty Revenue $127.9* $128.2 0% R&D Revenue $14.3 $18.3 (22%) License Revenue $1.0 $48.3 N/A Total Revenue $279.9** $304.6 (8%) *These results
Slide 5: Revenues From Proprietary Commercial Medicines
Revenues From Proprietary Commercial Medicines Proprietary Commercial Product Net Sales ($M)
Slide 6: VIVITROL Performance and Expectations
VIVITROL® Performance and Expectations Q2 year-over-year net sales growth of 16% to $88.2M, driven by underlying unit growth of 12% Recognized $3M favorable revenue impact related to Medicaid utilization adjustment Gross-to-net deductions of 48% in Q2’19, compared to 49% in Q1’19 and 49% in Q2’18 20
Slide 7: ARISTADA Performance and Expectations
ARISTADA® Performance and Expectations Q2 year-over-year net sales growth of 44% to $48.4M Gross-to-net deductions of 48%, compared to 49% in Q1’19 and 43% in Q2’18 Prescriptions increased by 13% sequentially and 43% year-over-year during the quarter, on a TRx months of therapy (MOT) basis1 2019 ful
Slide 8: Financial Expectations for Year Ending Dec. 31, 2019
(in millions, except per share amounts) Financial Expectations for Year Ending Dec. 31, 2019† Revenues $1,140 – 1,190 COGS $180 – 190 R&D Expense $450 – 480 SG&A Expense $590 – 620 Amortization of Intangible Assets ~$40 Net Interest Expense $5 to $10 Income Tax Expense $10 to $15 GAAP Net Loss $(135
Slide 9: VIVITROL: Opportunities to Increase Utilization and Drive Growth
VIVITROL®: Opportunities to Increase Utilization and Drive Growth Opportunities have continued to arise at the state and community level as states have adopted more targeted policies in criminal justice and community settings, and have passed legislation to remove certain barriers that limit access
Slide 10: ARISTADA: Positioned for Long-Term Growth
ARISTADA®: Positioned for Long-Term Growth ARISTADA underlying prescription trends demonstrated solid growth On a TRx MOT basis, Q2 sequential growth was 13%, compared to the broader atypical long-acting injectable (aLAI) market growth of 6% sequentially Year-over-year, Q2 ARISTADA TRx MOT grew 43%
Slide 11: ALKS 3831
ALKS 3831 Investigational, novel, once-daily, oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and the treatment of adults with bipolar I disorder Designed to provide antipsychotic efficacy of olanzapine with a favorable weight profile Reported positive topli
Slide 12: ALKS 4230
ALKS 4230 Novel, engineered fusion protein designed to selectively expand tumor-killing immune cells while avoiding the activation of immunosuppressive cells by preferentially binding to the intermediate-affinity interleukin-2 (IL-2) receptor complex ARTISTRY-1 phase 1/2 study Monotherapy expansion
Slide 13: Diroximel Fumarate (DRF)
Diroximel Fumarate (DRF) Investigational product for the treatment of relapsing forms of multiple sclerosis (MS) License and collaboration agreement with Biogen announced in Q4’17 Biogen intends to market diroximel fumarate under the conditionally approved brand name VUMERITY™ Data on DRF efficacy a
Slide 14: News Flow Expected in 2019
News Flow Expected in 2019 ARISTADA® Report topline results for ALPINE phase 3b study (Q2) ALKS 3831 Present ENLIGHTEN-2 data at medical meeting (Q2) Submit NDA for schizophrenia and bipolar I disorder (Q4) VIVITROL® Present and publish data on detox and induction strategies Diroximel fumarate Repor
Slide 15: www.alkermes.com
www.alkermes.com